Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
MALVERN, Pa., April 08, 2024 -- Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the...
Source: marketscreener.com